SPECT/CT in Early Response Assessment of Patients with Metastatic Castration-Resistant Prostate Cancer Receiving 177Lu-PSMA-617
Ridvan Arda Demirci,Roman Gulati,Jessica E. Hawley,Todd Yezefski,Michael C. Haffner,Heather H. Cheng,Robert B. Montgomery,Michael T. Schweizer,Evan Y. Yu,Peter S. Nelson,Delphine L. Chen,Amir Iravani
DOI: https://doi.org/10.2967/jnumed.124.267665
2024-12-04
Journal of Nuclear Medicine
Abstract:177 Lu-PSMA-617 (LuPSMA) is a newly established treatment for patients with metastatic castration-resistant prostate cancer (mCRPC), but survival outcomes vary widely, and predictors of treatment responses are needed. This study investigated the role of total tumor volumes (TTVs) and new lesions (NLs) determined by LuPSMA SPECT/CT in early cycles to predict subsequent outcomes in a real-world practice setting. Methods: Between June and December 2022, consecutive patients with mCRPC who received at least 2 administrations of LuPSMA with SPECT/CT 24 h after treatment were retrospectively reviewed. We evaluated associations between TTVs and the appearance of NLs at cycles 2 and 3 with subsequent prostate-specific antigen (PSA) progression-free survival and overall survival (OS) using multivariate Cox regression. All analyses were adjusted for changes in PSA level relative to baseline. Results: Sixty-six mCRPC patients (median age, 74 y) received a median of 4 (interquartile range, 3–5) cycles of LuPSMA. Median follow-up starting at cycle 2 was 42 wk (interquartile range, 33–48 wk), with 24 of 66 patients deceased at the time of the analysis. Changes in TTV measured at the start of cycles 2 and 3 relative to baseline correlated significantly with corresponding changes in PSA level ( r = 0.55 and 0.56), but absolute TTVs did not correlate significantly ( r = 0.00 and 0.18). Patients with a higher absolute TTV at the start of cycle 2 had worse PSA progression-free survival and OS (hazard ratio [HR], 1.4 [95% CI, 1.1–1.8] and 2.1 [95% CI, 1.5–2.9]), with consistent results at the start of cycle 3 (HR, 2 [95% CI, 1.4–2.9] and 2 [95% CI, 1.2–3.2]). NLs were identified in 13 of 66 and 11 of 51 patients at the start of cycles 2 and 3. NLs at the start of cycle 2 were associated with worse OS (HR, 5.8 [95% CI, 1.9–17.5]), with consistent results at the start of cycle 3 (HR, 4.9 [95% CI, 1.3–18.6]). In multivariate analysis, a higher TTV and the appearance of NLs at the start of cycles 2 and 3 were independently associated with poorer OS. Conclusion: Higher TTVs and NLs on LuPSMA SPECT/CT at the start of cycles 2 and 3 were independently associated with higher risk of death. These measures provided prognostic information independent of changes in PSA. Development of prognostic and predictive models including TTV, NLs, and PSA changes is warranted.
radiology, nuclear medicine & medical imaging